表紙
市場調査レポート

グリクラジドの中国市場

Investigation Report on China Gliclazide Market, 2010-2019

発行 China Research and Intelligence 商品コード 334100
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
グリクラジドの中国市場 Investigation Report on China Gliclazide Market, 2010-2019
出版日: 2015年07月02日 ページ情報: 英文 30 Pages
概要

中国におけるグリクラジドの売上額は、2005年から2014年にかけて12%のCAGRで拡大し、2014年には1億3700万人民元に達しました。

当レポートでは、中国のグリクラジド市場について調査し、グリクラジドの効能・効果、中国市場における特許および承認の状況、売上・販売量の推移と予測、価格動向、主要メーカーと市場シェア、競合環境とその展望、主要メーカーのプロファイルなどをまとめています。

第1章 グリクラジドの関連概念

  • 適応
  • 世界市場における販売状況

第2章 中国におけるグリクラジドの市場プロファイル

  • 特許状況
  • 主要製薬会社
  • 市場規模

第3章 中国におけるグリクラジドの販売状況調査

  • 販売額
    • 総販売額
    • 地域別の販売額
  • 販売量
    • 総販売量
    • 地域別の販売数

第4章 中国におけるグリクラジドの主要製薬会社の市場シェア調査

  • 販売額ベースの市場シェア
  • 販売量ベースの市場シェア

第5章 中国におけるグリクラジドの剤形に関する調査

  • 剤形別の市場シェア:販売額ベース
  • 剤形別の市場シェア:販売量ベース

第6章 中国の病院におけるグリクラジドの基準価格

  • Servier (Tianjin) Pharmaceutical Co., Ltd (商品名:Diamicron)
  • Servier (France)
  • Tianjin Huajin Pharmaceutical Co., Ltd
  • Helioeast
  • Beijing Wansheng Pharmaceutical Co., Ltd
  • Guilin Hwasun Pharmaceutical Co., Ltd
  • GuoGuang

第7章 中国市場におけるグリクラジドの主要製薬会社

  • Servier (Tianjin) Pharmaceutical Co., Ltd
  • Servier (France)
  • Tianjin Huajin Pharmaceutical Co., Ltd
  • NanChang Helioeast Pharmaceutical Co.,Ltd
  • Beijing Wansheng Pharmaceutical Co., Ltd

第8章 中国におけるグリクラジドの市場見通し

  • 市場規模の予測
  • 競合情勢の予測
目次
Product Code: 1507261

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, gliclazide and glimepiride are the common drugs in the class of sulfonylurea.

First developed by Servier (France), gliclazide entered China in 1985. Gliclazide acts in a mild way and since it can inhibit platelet aggregation and thrombosis as well as lower blood viscosity, it both reduces blood glucose and prevents microangiopathy. Before Servier (France) developed gliclazide sustained-release tablet which should be given at a dose of 30 mg once daily in Nov. 2000 only gliclazide immediate-release tablet, a 80 mg formulation that should be taken in two divided doses daily, was available in the market.

Although over ten local enterprises got the approval to produce gliclazide, they all took up a small market share, among which Servier (Tianjin) Pharmaceutical Co., Ltd ranked first despite a share of less than 2% due to the support from Servier (France) that began to cooperate with it in 1987 to produce gliclazide sustained release tablet.

According to CRI's market survey, in 2014, Servier (France) and its subsidiary Servier (Tianjin) Pharmaceutical Co., Ltd took up a market share of about 96% for sales value in China while other companies like Tianjin Huajin Pharmaceutical Co., Ltd, Helioeast and Beijing Wansheng Pharmaceutical Co., Ltd shared the rest market share. The sales value of gliclazide was about CNY 137 million in 2014 and CAGR reached 12% during the period of 2005-2014.

The market size of gliclazide is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:

  • market size of gliclazide in China
  • major manufacturers of gliclazide for Chinese market and their market share
  • retail price of gliclazide in Chinese market
  • market outlook of gliclazide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Gliclazide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Gliclazide in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Gliclazide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Gliclazide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Gliclazide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Gliclazide in Chinese Hospitals in 2014

  • 6.1. Servier (Tianjin) Pharmaceutical Co., Ltd (Trade Name: Diamicron)
  • 6.2. Servier (France)
  • 6.3. Tianjin Huajin Pharmaceutical Co., Ltd
  • 6.4. Helioeast
  • 6.5. Beijing Wansheng Pharmaceutical Co., Ltd
  • 6.6. Guilin Hwasun Pharmaceutical Co., Ltd
  • 6.7. GuoGuang

7. Major Manufacturers of Gliclazide in Chinese Market, 2010-2014

  • 7.1. Servier (Tianjin) Pharmaceutical Co., Ltd
  • 7.2. Servier (France)
  • 7.3. Tianjin Huajin Pharmaceutical Co., Ltd
  • 7.4. NanChang Helioeast Pharmaceutical Co.,Ltd
  • 7.5. Beijing Wansheng Pharmaceutical Co., Ltd

8. Market Outlook of Gliclazide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Registration Information of Gliclazide in China
  • Chart Approval Status of Gliclazide in China
  • Chart Sales Status of Gliclazide in China, 2010-2014
  • Chart Sales Value of Gliclazide in China, 2010-2014
  • Chart Sales Value of Gliclazide by Regions in China, 2010-2014
  • Chart Sales Value of Gliclazide Tablets in China, 2010-2014
  • Chart Sales Value of Gliclazide Capsules in China, 2010-2014
  • Chart Market Share of Major Manufacturers of Gliclazide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Gliclazide Made by Servier (Tianjin) Pharmaceutical Co., Ltd, 2010-2014
  • Chart Sales Value and Market Share of Gliclazide Made by Servier (France), 2010-2014
  • Chart Sales Value and Market Share of Gliclazide Made by Tianjin Huajin Pharmaceutical Co., Ltd, 2010-2014
  • Chart Sales Value and Market Share of Gliclazide Made by Helioeast, 2010-2014
  • Chart Price of Gliclazide Made by Servier (Tianjin) Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Gliclazide Made by Tianjin Huajin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Gliclazide Made by Servier (France) in Some Chinese Cities in 2014
  • Chart Price of Gliclazide Made by Helioeast in Some Chinese Cities in 2014
Back to Top